Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES
Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES
复制标题
DOI：
10.1161/circulationaha.119.043826
复制
发表时间：
2019-12-17
期刊：
影响因子：
37.8
通讯作者：
Steg, Philippe Gabriel
中科院分区：
文献类型：
--
作者：
Jukema, J. Wouter;Zijlstra, Laurien E.;Steg, Philippe Gabriel
背景：降低导致动脉粥样硬化的脂蛋白，包括低密度脂蛋白胆固醇(LDL-C)，可降低缺血性卒中的风险。然而，人们对极低的低密度脂蛋白水平和出血性中风的潜在风险提出了担忧。在18924名最近患有急性冠脉综合征且致动脉粥样硬化脂蛋白升高的患者中，尽管强化他汀类药物治疗，将低密度脂蛋白水平定在25-50 mg/dL，并避免持续的低密度脂蛋白，但奥德赛的结果还是比较了PCSK9抑制剂alirocumab和安慰剂。
BACKGROUND: Lowering of atherogenic lipoproteins, including low-density lipoprotein cholesterol (LDL-C), reduces the risk of ischemic stroke. However, concerns have been raised about very low LDL-C levels and a potential increased risk of hemorrhagic stroke. ODYSSEY OUTCOMES compared the PCSK9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome and elevated atherogenic lipoproteins, despite intensive statin therapy, targeting LDL-C levels of 25 to 50 mg/dL and avoiding sustained LDL-C